HERIZON-GEA-01

NCT05152147 📎

Regimen

Experimental
zanidatamab + chemotherapy + tislelizumab, or zanidatamab + chemotherapy
Control
trastuzumab + chemotherapy

Population

HER2-positive advanced gastric/GEJ adenocarcinoma as first-line therapy

Key finding

Topline 2025: both zani arms PFS HR ~0.65 vs control; zani+tisle+chemo mOS >7 mo improvement vs trastuzumab+chemo; ESMO 2025 LBA; full peer-reviewed results pending 2026